SCHEMBL2647594

SCHEMBL2647594

CCCCc1c(C(C)C)nc(C(C)C)c(C(=O)O)c1-c1ccc(F)cc1

nearest known ligand 0.70

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GCGR P47871 20/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651071 0.83 GCGR (0.56) GCGR
SCHEMBL2649227 0.83 GCGR (0.69) GCGR
SCHEMBL2647251 0.83 GCGR (1.00) GCGR
SCHEMBL2662976 0.81 GCGR (1.00) GCGR
SCHEMBL2648285 0.81 GCGR (1.00) GCGR
SCHEMBL9870949 0.80 GCGR (0.56) GCGR
SCHEMBL9870644 0.80 GCGR (0.56) GCGR
SCHEMBL2647181 0.79 GCGR (1.00) GCGR
SCHEMBL2647342 0.79 GCGR (0.86) GCGR
SCHEMBL8879628 0.79 DHODH (0.55) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed